MONTREAL, QUEBEC, CANADA -- (MARKET WIRE) -- February 14, 2007 -- Royalmount Pharma, an emerging pharmaceutical company, is pleased to announce that the U.S. National Cancer Institute ("NCI") has initiated a clinical trial to assess the tolerability, target tissue levels, biological markers of activity, and pharmacodynamics of RM1812 in colorectal cancer patients.
